Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Since 1972, shares of Eli Lilly have generated a total return north of 100,000%. Clearly, Lilly has been a consistent ...

With so many kids already taking weight loss injectables like Ozempic, a new finding from the company behind the blockbuster ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the ...

Although women lost more weight, all participants saw significant decreases in total body weight on all doses of the medication.

While it might not perfectly follow in the larger biotech's footsteps, TERN-601 has the potential to be one of the safer, ...

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also ...

However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...

Millions turn to compounded versions of popular weight loss drugs amid shortages and high costs.

Eli Lilly and Company (NYSE:LLY) was a part of 100 hedge fund portfolios at the end of Q2 2024, down from 109 in the previous ...